France
· Delayed Price · Currency is EUR GenSight Biologics Statistics
Total Valuation
GenSight Biologics has a market cap or net worth of EUR 31.96 million. The enterprise value is 47.70 million.
| Market Cap | 31.96M |
| Enterprise Value | 47.70M |
Important Dates
The next estimated earnings date is Thursday, January 23, 2025.
| Earnings Date | Jan 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GenSight Biologics has 115.16 million shares outstanding. The number of shares has increased by 44.26% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 115.16M |
| Shares Change (YoY) | +44.26% |
| Shares Change (QoQ) | +63.67% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 13.29% |
| Float | 43.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.36 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.37 |
| EV / Sales | 24.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.02 |
Financial Position
The company has a current ratio of 0.77
| Current Ratio | 0.77 |
| Quick Ratio | 0.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.43 |
| Interest Coverage | -9.99 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -78.84% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 179,636 |
| Profits Per Employee | -1.83M |
| Employee Count | 16 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.30% in the last 52 weeks. The beta is 2.30, so GenSight Biologics's price volatility has been higher than the market average.
| Beta (5Y) | 2.30 |
| 52-Week Price Change | -41.30% |
| 50-Day Moving Average | 0.32 |
| 200-Day Moving Average | 0.36 |
| Relative Strength Index (RSI) | 38.52 |
| Average Volume (20 Days) | 394,036 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GenSight Biologics had revenue of EUR 1.98 million and -20.11 million in losses. Loss per share was -0.30.
| Revenue | 1.98M |
| Gross Profit | 1.98M |
| Operating Income | -20.01M |
| Pretax Income | -20.10M |
| Net Income | -20.11M |
| EBITDA | -19.21M |
| EBIT | -20.01M |
| Loss Per Share | -0.30 |
Balance Sheet
The company has 6.94 million in cash and 22.68 million in debt, giving a net cash position of -15.74 million or -0.14 per share.
| Cash & Cash Equivalents | 6.94M |
| Total Debt | 22.68M |
| Net Cash | -15.74M |
| Net Cash Per Share | -0.14 |
| Equity (Book Value) | -24.83M |
| Book Value Per Share | -0.24 |
| Working Capital | -3.85M |
Cash Flow
In the last 12 months, operating cash flow was -15.80 million and capital expenditures -11,000, giving a free cash flow of -15.81 million.
| Operating Cash Flow | -15.80M |
| Capital Expenditures | -11,000 |
| Free Cash Flow | -15.81M |
| FCF Per Share | -0.14 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,012.40% |
| Pretax Margin | -1,017.36% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GenSight Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.26% |
| Shareholder Yield | -44.26% |
| Earnings Yield | -108.70% |
| FCF Yield | -49.48% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GenSight Biologics has an Altman Z-Score of -4.69. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.69 |
| Piotroski F-Score | n/a |